Cordycepin/hydroxyurea synergy allows low dosage efficacy of cordycepin in MOLT-4 leukemia cells

Anticancer Research

Volumn 27, Issue 5 A, 2007, Pages 3143-3146

  Wehbe Janek, Hania ^a,b   Qiang, Shi ^a,c   Kearney, Christopher M ^a  

^a BAYLOR UNIVERSITY   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Cordycepin; Hydroxyurea; Leukemia; Synergy

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; CORDYCEPIN; HYDROXYUREA; PENTOSTATIN;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MOLTING; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DEOXYADENOSINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; HYDROXYUREA; LEUKEMIA, T-CELL;

EID: 35348970357     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Zieve GW, Feeney RJ and Roemer EJ: Cordycepin disrupts the microtubule networks and arrests Nil 8 hamster fibroblasts at the onset of mitosis. Cell Motil Cytoskeleton 7: 337-346, 1987.
2. Kim HG, Shresha B, Lim SY, Toon DH, Chang WC, Shin D-J, Han SK, Park SM, Park JH, Park HI, Sung J-M, Jang Y, Chung N, Hwang K-C and Kin TW: Cordycepin inhibits lipopolysaccharide-induced inflammation by the suppression of NF-κB through Akt and p38 inhibition in RAW 264.7 macrophage cells. Eur J Pharmacol 545: 192-199, 2006.
3. Cho H-J, Cho JY, Rhee MH and Park H-J: Cordycepin (3′- deoxyadenosine) inhibits human platelet aggregation in a cyclic AMP- and cyclic GMP-dependent manner. Eur J Pharmacol 558: 43-51, 2007.
4. Sugar AM and McCaffrey RP: Antifungal activity of 3′-deoxyadenosine (cordycepin). Antimicrob Agents Chemother 42: 1424-1427, 1998.
5. Rottenberg ME, Masocha W, Ferella M, Petitto-Assis F, Goto H, Kristensson K, McCaffrey R and Wigzell H: Treatment of African trypanosomiasis with cordycepin and adenosine deaminase inhibitors in a mouse model. J Infect Dis 192: 1658-1665, 2005
6. Kodama EN, McCaffrey RP, Yusa K and Mitsuya H: Antileukemic activity and mechanism of action of cordycepin against terminal deoxynucleotidyl transferase-positive (TdT+) leukemic cells. Biochem Pharmacol 59: 273-281, 2000.
7. Wu W-C, Hsiao J-R, Lian Y-Y, Lin C-Y and Huang B-M: The apoptotic effect of cordycepin on human OEC-M1 oral cancer cell line. Cancer Chemother Pharmacol 60: 103-111, 2007.
8. Thomadaki H, Tsiapalis CM and Scorilas A: The effect of the polyadenylation inhibitor cordycepin on human Molt-4 and Daudi leukaemia and lymphoma cell lines. Cancer Chemother Pharmacol: 2007 Jun 13 [Epub ahead of print].
9. Adamson RH, Zaharevitz DW and Johns DG: Enhancement of the biological activity of adenosine analogs by the adenosine deaminase inhibitor 2′-deoxycoformycin. Pharmacology 15: 84-89, 1977.
10. Chang H-M, Oakes J, Olsson A, Panaitescu L, Britt BM, Kearney CM and Kane RR: Synthesis and in vitro evaluation of adenosine deaminase resistant N-6 aminal and thioaminal prodrugs of cordycepin. Lett Drug Des Discov 2: 184-193, 2005.
11. Oliver FJ, Collins MK and Lopez-Rivas A: Overexpression of a heterologous thymidine kinase delays apoptosis induced by factor deprivation and inhibitors of deoxynucleotide metabolism. J Biol Chem 272: 10624-10630, 1997.
12. Donehower RC: Hydroxyurea. In: Cancer Chemotherapy and Biotherapy. Chabnet BC and Longo DL (eds.). Philadelphia, Lippincott-Raven, pp. 253-261, 1996.
13. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
14. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
15. de Montalembert M, Brousse V, Elie C, Bernaudin F, Shi J and Landais P: Long-term HU treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica 91: 125-128, 2006.
16. Wadler S, Horowitz R, Zhang HY and Schwartz EL: Effects of perturbations of pools of deoxyribonucleoside triphosphates on expression of ribonucleotide reductase, a G1/S transition state enzyme, in p53-mutated cells. Biochem Pharmacol 55: 1353-1360, 1998.
17. Boucher PD, Ostruszka LJ and Shewach DS: Synergistic enhancement of herpes simplex virus thymidine kinase/ganciclovir-mediated cytoxicity by hydroxyurea. Cancer Res 60: 1631-1636, 2000.
18. Lallas GC, Courtis N and Havredaki M: K562 cell sensitization to 5-fluorouracil- or interferon-alpha-induced apoptosis via cordycepin (3′-deoxyadenosine): fine control of cell apoptosis via poly(A) polymerase up-regulation. Int J Biol Markers 19: 58-66, 2004.
19. Izuta S, Kohsaka-Ichikawa M, Yamaguchi T and Saneyoshi M: 3′-Deoxyribonucleotides inhibit eukaryotic DNA primase. J Biochem (Tokyo) 119: 1038-1044, 1996.
20. Zieve GW and Roemer EJ: Cordycepin rapidly collapses the intermediate filament networks into juxtanuclear caps in fibroblasts and epidermal cells. Exp Cell Res 177: 19-26, 1988.
21. Nakamura K, Yoshikawa N, Yamaguchi Y, Kagota S, Shinozuka K and Kunitomo M: Antitumor effect of cordycepin (3′-deoxyadenosine) on mouse melanoma and lung carcinoma cells involves adenosine A3 receptor stimulation. Anticancer Res 26: 43-47, 2006.